Bregt S Kappelhoff

904 total citations
21 papers, 693 citations indexed

About

Bregt S Kappelhoff is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Bregt S Kappelhoff has authored 21 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 9 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Bregt S Kappelhoff's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (9 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Bregt S Kappelhoff is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (9 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Bregt S Kappelhoff collaborates with scholars based in Netherlands, United States and Germany. Bregt S Kappelhoff's co-authors include Alwin D. R. Huitema, Jos H. Beijnen, Jan W. Mulder, Frank van Leth, Kristel M. L. Crommentuyn, Thomas R. MacGregor, Joep MA Lange, Monique M. R. de Maat, Pieter L. Meenhorst and Patrick Robinson and has published in prestigious journals such as Blood, PLoS ONE and Clinical Pharmacokinetics.

In The Last Decade

Bregt S Kappelhoff

20 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bregt S Kappelhoff Netherlands 11 530 349 124 100 96 21 693
Michael L. Lim United States 9 502 0.9× 305 0.9× 99 0.8× 66 0.7× 155 1.6× 11 574
Sandra M. Geletko United States 10 365 0.7× 210 0.6× 108 0.9× 83 0.8× 85 0.9× 16 557
Véronique Reliquet France 16 404 0.8× 257 0.7× 154 1.2× 43 0.4× 149 1.6× 36 630
Jonathan Uy United States 10 280 0.5× 222 0.6× 60 0.5× 81 0.8× 26 0.3× 24 532
Miranda Murray United Kingdom 15 573 1.1× 300 0.9× 277 2.2× 126 1.3× 116 1.2× 29 810
Birgit Kvinesdal Denmark 14 308 0.6× 215 0.6× 202 1.6× 23 0.2× 77 0.8× 35 754
Wim Parys Belgium 9 349 0.7× 264 0.8× 85 0.7× 23 0.2× 59 0.6× 13 655
Anthony T. Podany United States 18 573 1.1× 286 0.8× 220 1.8× 81 0.8× 135 1.4× 54 844
M Youle United Kingdom 14 432 0.8× 258 0.7× 186 1.5× 42 0.4× 170 1.8× 35 665
Daniel Seekins United States 19 532 1.0× 324 0.9× 211 1.7× 27 0.3× 161 1.7× 30 746

Countries citing papers authored by Bregt S Kappelhoff

Since Specialization
Citations

This map shows the geographic impact of Bregt S Kappelhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bregt S Kappelhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bregt S Kappelhoff more than expected).

Fields of papers citing papers by Bregt S Kappelhoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bregt S Kappelhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bregt S Kappelhoff. The network helps show where Bregt S Kappelhoff may publish in the future.

Co-authorship network of co-authors of Bregt S Kappelhoff

This figure shows the co-authorship network connecting the top 25 collaborators of Bregt S Kappelhoff. A scholar is included among the top collaborators of Bregt S Kappelhoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bregt S Kappelhoff. Bregt S Kappelhoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kharawala, Saifuddin, et al.. (2021). The relationship between cognition and functioning in schizophrenia: A semi-systematic review. Schizophrenia Research Cognition. 27. 100217–100217. 70 indexed citations
3.
4.
Stevanović, Jelena, et al.. (2016). Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PLoS ONE. 11(10). e0163550–e0163550. 6 indexed citations
5.
Postma, Maarten J., Bregt S Kappelhoff, Marinus van Hulst, & J. R. B. J. Brouwers. (2012). Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. Journal of Medical Economics. 15(5). 878–886. 7 indexed citations
6.
Hoogendoorn, Martine, Bregt S Kappelhoff, Jetty A. Overbeek, Emiel F.�M. Wouters, & Maureen Rutten‐van Mölken. (2012). Which long-acting bronchodilator is most cost-effective for the treatment of COPD?. PubMed. 70(8). 357–64. 7 indexed citations
7.
Boersma, Cornelis, Bregt S Kappelhoff, & Maarten J. Postma. (2009). Administration Advantages and Cost-Savings with Dabigatran Etexilate Versus Parenteral Agents for Thromboprophylaxis After Major Orthopaedic Surgery in the Netherlands.. Blood. 114(22). 1383–1383. 1 indexed citations
8.
Finnern, Henrik W., et al.. (2007). Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Effectiveness and Resource Allocation. 5(1). 15–15. 8 indexed citations
9.
Leth, Frank van, Bregt S Kappelhoff, David W. Johnson, et al.. (2006). Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy. AIDS Research and Human Retroviruses. 22(3). 232–239. 63 indexed citations
10.
Kappelhoff, Bregt S, Alwin D. R. Huitema, Jan M. Prins, et al.. (2005). Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals. Clinical Pharmacokinetics. 44(8). 849–861. 49 indexed citations
11.
Kappelhoff, Bregt S, Frank van Leth, Thomas R. MacGregor, et al.. (2005). Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study. Antiviral Therapy. 10(1). 145–155. 78 indexed citations
12.
Kappelhoff, Bregt S, Alwin D. R. Huitema, Pieter L. Meenhorst, et al.. (2005). Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV‐1‐infected patients. British Journal of Clinical Pharmacology. 60(3). 276–286. 15 indexed citations
13.
Kappelhoff, Bregt S, Alwin D. R. Huitema, & Jos H. Beijnen. (2005). Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined?. Drugs in R&D. 6(2). 61–69. 1 indexed citations
14.
Kappelhoff, Bregt S, Alwin D. R. Huitema, Frank van Leth, et al.. (2005). Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study. HIV Clinical Trials. 6(5). 254–261. 22 indexed citations
15.
Kappelhoff, Bregt S, Alwin D. R. Huitema, Albert T.A. Mairuhu, Jan H.M. Schellens, & Jos H. Beijnen. (2005). No pharmacokinetic drug???drug interaction between nevirapine and paclitaxel. Anti-Cancer Drugs. 16(6). 627–630. 2 indexed citations
16.
Crommentuyn, Kristel M. L., Bregt S Kappelhoff, Jan W. Mulder, et al.. (2005). Population pharmacokinetics of lopinavir in combination with ritonavir in HIV‐1‐infected patients. British Journal of Clinical Pharmacology. 60(4). 378–389. 57 indexed citations
17.
Kappelhoff, Bregt S, Alwin D. R. Huitema, & Jos H. Beijnen. (2005). Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs. Clinical Pharmacokinetics. 44(4). 439–440. 6 indexed citations
18.
Kappelhoff, Bregt S, Kristel M. L. Crommentuyn, Monique M. R. de Maat, et al.. (2004). Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs. Clinical Pharmacokinetics. 43(13). 845–853. 93 indexed citations
19.
Kappelhoff, Bregt S, Alwin D. R. Huitema, Kristel M. L. Crommentuyn, et al.. (2004). Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV‐1‐infected patients. British Journal of Clinical Pharmacology. 59(2). 174–182. 30 indexed citations
20.
Kappelhoff, Bregt S, Hilde Rosing, Alwin D. R. Huitema, & Jos H. Beijnen. (2003). Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. Journal of Chromatography B. 792(2). 353–362. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael L. Lim Breakdown of academic impact, for papers by Sandra M. Geletko Breakdown of academic impact, for papers by Véronique Reliquet Breakdown of academic impact, for papers by Jonathan Uy Breakdown of academic impact, for papers by Miranda Murray Breakdown of academic impact, for papers by Birgit Kvinesdal Breakdown of academic impact, for papers by Wim Parys Breakdown of academic impact, for papers by Anthony T. Podany Breakdown of academic impact, for papers by M Youle Breakdown of academic impact, for papers by Daniel Seekins
Rankless by CCL
2026